All Stories

Arbutus jettisons 57% of staff, ceases in-house research

Arbutus Biopharma is stripping its workforce back to just a “core team” needed to oversee mid-stage trials of the biotech's potential functional cure for hepatitis B.

Mar 27, 2025 - 23:12
 0
Arbutus jettisons 57% of staff, ceases in-house research
Arbutus Biopharma is stripping its workforce back to just a “core team” needed to oversee mid-stage trials of the biotech's potential functional cure for hepatitis B.
Read More

Tags:

Previous Article

Candel’s lung cancer survival data light path toward pivotal trial in subpopulation

Next Article

Equillium misses primary endpoint, plus 2 key secondaries, but still plans appro...

Related Posts

VC firm Kineticos launches biotech to develop fresh approach to antibiotic resistance

VC firm Kineticos launches biotech to develop fresh app...

Feb 24, 2025  0

AstraZeneca details $2.5B investment in China's political center, funding R&D center, biotech pacts

AstraZeneca details $2.5B investment in China's politic...

Mar 21, 2025  0

Pliant pauses phase 2 lung fibrosis trial on advice of safety committee

Pliant pauses phase 2 lung fibrosis trial on advice of ...

Feb 10, 2025  0